San Francisco, 27 February 2019: The Report Point of Care (POC) Diagnostics/Testing Market Size, Share & Trends Analysis
Report By Product (Glucose Testing, Hb1Ac, Coagulation, Fertility, Cardiac
Markers, Hematology, Urinalysis), By End-use, And Segment Forecasts, 2018 -
2024
The global point of care (PoC) diagnostics market is
anticipated to reach USD 20.9 billion by 2024, according to a new report by
Grand View Research, Inc. Rise in the R&D funding and
research activities amongst the market players in order to introduce novel POC
tests and devices for ease of disease detection and monitoring is expected to
fuel industrial progress through to 2024.
Moreover, the introduction of favorable
regulatory initiatives in order to promote the development and adoption of POC
diagnostic tests is anticipated to propel growth in the coming years.
Furthermore, advancement of diagnostic laboratories and adaptation of more
integrated and automated lab systems are also factors expected to fuel demand
for advanced workflow systems and drive the digital pathology and workflow
segment through to 2024.
Access Research Report of Point of Care
Diagnostics Market @ www.grandviewresearch.com/industry-analysis/point-of-care-poc-diagnostics-industry
Further key findings from the report suggest:
· Glucose testing accounted for the largest
share in revenue in 2015 owing to the higher prevalence of diabetes. Presence of
significant product portfolio pertaining to glucose testing in the market and
the presence of a number of major players as wells as local manufacturers from
different regions are factors attributive to contribute substantially to the
revenue generated.
· Hb1Ac POC tests are more reliable for
glucose testing and due to the vast patient base for diabetes management, this
segment is second in terms of revenue generation in the POC market only to its
counterpart. Owing to the presence of glucose testing segment as a potential
market and growing cost effectiveness of Hb1Ac tests, it is expected that over
the coming decade it will witness considerable growth in demand and usage
· POC tests for infectious disease testing,
is another segment of prime activity in the point of care industry. This
segment includes rapid diagnostic tests for a considerable number of diseases
including HIV, HBV, RSV, HPV, Influenza, HCV, MRSA, TB/dr-TB & HSV among
others.
· Owing to the growing incidence of a number
of infectious diseases, initiatives taken by a number of governments to
implement early diagnosis and screening, and development of rapid tests able to
distinguish between a wide number of pathogens this segment has been observed
to be at the demand receiving end in the industry for the better half of the
last decade and is only expected to witness growth in demand.
· Hospitals are estimated to be the dominant
end-users for POC diagnosis industry owing to higher penetration of products
and comparatively higher usage rate for disease monitoring and diagnosis.
· North America dominated the market in 2015,
with over 43% of total revenue. Presence of major entities with widespread
distribution network coupled with significant number of research endeavors
carried out in the U.S is supportive for the largest share of region. Moreover,
point of care diagnostics is a relatively more advanced segment of in vitro
diagnostics and owing to the presence of high R&D expenditure,
availability of a technologically advanced healthcare infrastructure along with
the presence of a number of ongoing government funded research projects are
factors accounting for the region’s large share.
· Asia Pacific is projected to witness
lucrative growth in the coming years owing to the developments carried out in
developing economies herein in order to develop the healthcare infrastructure
and reduce the incidence of target diseases.
· Major participants of this market include
Roche, Abbott Laboratories, Siemens Healthcare, Danaher Corporation,
BioMerieux, Johnson & Johnson, Abaxis Inc., Alere Inc., Qiagen N.V.,
Spectral Diagnostics, Instrumentation Laboratory, Nova Biomedical, Nipro
Diagnostics, Trinity Biotech, and Sekisui.
· Participants are involved in adopting
competitive strategies in order to enhance the market presence. These companies
are also involved in collaborations with hospitals in order to maintain the
market share.
· For instance, in April 2015, Nipro
diagnostics participated in an industry event named AMCP (Academy of Managed
Care Pharmacy) in support of providing care to the patients with diabetes.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/clinical-diagnostics
Grand View Research has segmented point of
care diagnostics market on the basis of application, end-use, and region:
Global Point of Care Diagnostics Outlook,
by Product (Revenue, USD Million, 2013 - 2024)
·
Glucose Testing
·
Hb1Ac Testing
·
Infectious Disease Testing
·
Coagulation
·
Fertility
·
Cardiac markers
·
Primary care systems
·
Hematology
·
Decentralized Clinical Chemistry
·
Feces
·
Blood Gas/Electrolytes
·
Ambulatory Chemistry
·
Urinalysis
·
Drug Abuse Testing
Global Point of Care Diagnostics Outlook,
by End-use (Revenue, USD Million, 2013 - 2024)
·
Clinics
·
Hospitals
·
Assisted Living Healthcare Facilities
·
Laboratory
·
Others
Point of Care Diagnostics Regional Outlook
(Revenue, USD Million, 2013 - 2024)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
MEA
·
UAE
Access Press Release of
Point of Care Diagnostics Market@ www.grandviewresearch.com/press-release/global-point-of-care-diagnostics-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company, registered
in the State of California and headquartered in San Francisco. The company
provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
